Trial Profile
Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs: axitinib, sunitinib and sorafenib
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2015
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- 27 Oct 2015 New trial record